Effectiveness of PRRT for NETs in Germany: An Analysis of 450 Patients

#610

Introduction: Peptide receptor radionuclide therapy targets somatostatin receptors expressed on well-differentiated neuroendocrine neoplasms. Retrospective monocentric studies indicate that peptide receptor radionuclide therapy is an effective treatment for patients with neuroendocrine neoplasms.

Aim(s): We initiated a multi-institutional, prospective and board reviewed registry for patients treated with peptide receptor radionuclide therapy.

Materials and methods: Four hundred and fifty patients were included and followed for 17.7 months in median. Most patients were treated with Lutetium-177 (54%) or by both radionuclides. Origin of neuroendocrine neoplasms was pancreas (38%), small bowel 30%), unknown primary (19%) and lung (4%). Most neuroendocrine neoplasms were well-differentiated with a proliferation rate below 20% in 54% and were pretreated by one or more therapies in 73%.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Hörsch D

Authors: Hörsch D, Ezziddin S, Haug A, Gratz K, Dunkelmann S,

Keywords: PRRT,